Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review

Caroline Vinit1,2*, Sophie Georgin-Lavialle2,3, Aikaterini Theodoropoulou4,5, Catherine Barbier6, Alexandre Belot7,8, Manel Mejbri4,5, Pascal Pillet9, Jana Pachlopnik10, Sylvaine Poignant11, Charlotte Rebelle9, Andreas Woerner12, Isabelle Koné-Paut2,13† and Véronique Hentgen1,2

Background: Interleukin (IL)-1 inhibitors represent the main treatment in patients with colchicine-resistant/intolerant familial Mediterranean fever (crFMF), mevalonate kinase deficiency (MKD), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). However, the reasons for the use of IL-1 inhibitors in these diseases are still not completely clarified.

Objective: Identify real-life situations that led to initiating anakinra or canakinumab treatment in hereditary recurrent fevers (HRFs), combining data from an international registry and an up-to-date literature review.

Patients and Methods: Data were extracted from the JIRcohort, in which clinical information (demographic data, treatment, disease activity, and quality of life) on patients with FMF, MKD, and TRAPS was retrospectively collected. A literature search was conducted using Medline, EMBASE, and Cochrane databases.

Results: Complete data of 93 patients with HRF (53.8% FMF, 31.2% MKD, and 15.1% TRAPS) were analyzed. Data from both the registry and the literature review confirmed that the main reasons for use of IL-1 blockers were the following: failure of previous treatment (n = 57, 61.3% and n = 964, 75.3%, respectively), persistence of disease activity with frequent attacks (n = 44, 47.3% and n = 1,023, 79.9%) and/or uncontrolled inflammatory syndrome (n = 46, 49.5% and n = 398, 31.1%), severe disease complication or associated comorbidities (n = 38, 40.9% and n = 390, 30.4%), and worsening of...
patients’ quality of life (n = 36, 38.7% and n = 100, 7.8%). No reasons were specified for 12 (16.4%) JIRcohort patients and 154 (12%) patients in the literature.

**Conclusion:** In the absence of standardized indications for IL-1 inhibitors in crFMF, MKD, and TRAPS, these results could serve as a basis for developing a treat-to-target strategy that would help clinicians codify the therapeutic escalation with IL-1 inhibitors.

**Keywords:** autoinflammatory diseases, indications, treatment, hereditary recurrent fevers, interleukin-1 blockers, anakinra, canakinumab

**INTRODUCTION**

Hereditary recurrent fevers (HRFs) belong to the large group of autoinflammatory diseases (AIDs), whose name was first proposed by McDermott et al. in 1999 (1). This term describes inflammatory febrile attacks, with minimal involvement of the adaptive immune system in opposition to so-called autoimmune diseases.

Advances in the pathophysiological knowledge on HRFs have led to targeted therapies to improve patients’ quality of life, reduce the inflammatory response, and prevent amyloidosis. Based on the excess production of interleukin (IL)-1, the first patients with cryopyrin-associated periodic syndrome (CAPS) effectively treated with the IL-1 receptor antagonist anakinra were described in 2003 (2). The benefit of IL-1-blocking agents has subsequently been reported in the four prototypic monogenic AIDs (3–7). Anakinra received the market authorization (MA) for CAPS in 2013 and colchicine-resistant/intolerant familial Mediterranean fever (crFMF) in April 2020 in Europe (8). In addition, several studies reported its efficacy also in mevalonate kinase deficiency (MKD) and tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) patients (9–11). Canakinumab is licensed in adults and children from 2 years of age in the European Union (i) for first-line maintenance treatment in CAPS since 2009 and (ii) for familial Mediterranean fever (FMF), MKD, and TRAPS since 2017 (12). However, regulatory authorities’ indications may vary across countries.

IL-1 inhibitors are indicated for patients with (i) severe clinical manifestations, (ii) failure or severe side effects of treatment in MKD and TRAPS attacks, or (iii) crFMF (13). However, the precise clinical and biological criteria leading to the use of IL-1 inhibitors in these diseases are still unclear.

The main objective of our study was to identify actual criteria for the use of IL-1-blocking agents (anakinra and canakinumab) in patients with crFMF, MKD, or TRAPS using data from the Juvenile Inflammatory Rheumatism (JIR) cohort and an updated literature review.

**PATIENTS AND METHODS**

**JIRcohort**

The JIRcohort is an observational and multicenter international registry created in 2013 to collect data on patients with juvenile inflammatory rheumatic diseases. The cohort operates in specific modules; the module on AID has been running since April 2016. The participating centers can record both retrospective and prospective data, especially during follow-up visits. Patients are included in the JIRcohort after information and verification that they (or their legal guardian) are not opposed to the study and storage of their data. The JIRcohort protocol was approved by the French Ethics Committee (CCTIRS) on April 21, 2015 (decision number 14.302). The electronic form of the JIRcohort was approved by the National Commission of data processing and liberties (CNIL) on March 27, 2015 (decision number DR-2015-218).

Our survey collected only data from patients with FMF, MKD, and TRAPS treated with IL-1 inhibitors (anakinra and/or canakinumab). Selected patients came from 12 different centers in France and Switzerland. Since the HRFs Genoa criteria (14) were not available for all patients, the diagnosis of FMF, MKD, or TRAPS was established by the examining physician and investigator. Demographic data (age at diagnosis, genetics, comorbidities), therapeutic data, and data assessing disease activity and quality of life were collected at the last visit before starting IL-1 therapy. The presence of likely pathogens or pathogenic variants defined a confirmatory genotype according to the International Study Group for Systemic Autoinflammatory Diseases classification rules described elsewhere (15). Data evaluating disease activity included (i) biological features [C-reactive protein (CRP) and serum amyloid A protein (SAA) levels], (ii) flares’ characteristics (duration and frequency defined as more than three in 6 months), and (iii) the visual analog scale (VAS). The patient and physician rated this tool from 0 to 10, and an active disease was defined by a median VAS ≥ 3/10. The Auto-Inflammatory Diseases Activity Index (AIDAI) score validated and used in clinical practice was not, at this time, recorded in the JIRcohort. Data evaluating the quality of life included (i) number of hospitalizations or consultations, (ii) school or work impact (number of missing days, stress of exams triggering an attack, reduction of working times), (iii) severe daily asthenia and ongoing symptoms, and (iv) psychosocial impact (disease-related anxiety/depression). Therapeutic data included previous treatment(s), efficiency, and toxicity. Anakinra was prescribed continuously with daily injections or as on-demand treatment at the time of an attack. Patients without a follow-up visit recorded in the JIRcohort were excluded. The data extraction took place on May 15, 2020.
**Literature Review**

A literature search on the indications for IL-1 inhibitors in HRFs was performed using Medline, EMBASE, and Cochrane databases with mesh terms (Ilaris OR Canakinumab)/(Kineret OR Anakinra)/(IL-1 inhibitors) AND (familial Mediterranean fever OR FMF)/(mevalonate kinase deficiency OR MKD OR HIDS)/(periodic tumor necrosis factor receptor-related syndrome OR TRAPS). Additional research was conducted within the references of the retrieved papers. We identified 359 publications through this research before May 2020. We assessed all titles, abstracts, and full-length articles identified. Publications were eligible if they contained either data on anakinra and/or canakinumab in patients with FMF, MKD, or TRAPS as defined by the Tel Hashomer criteria (16) or a genetic analysis or a mevalonic aciduria dosage. After removing duplications, we excluded articles (i) that were not published in English nor French, (ii) with unavailable abstract or full text, and (iii) without data on canakinumab nor anakinra. After this process, 112 articles (randomized controlled trials, non-randomized trials, cohort studies, case reports, and case series) remained for analysis and were included in the study. Possible indications for IL-1 inhibitors were identified with data evaluating comorbidities, complications, disease activity, previous treatment(s), and tolerance.

**RESULTS**

**Patients JIRcohort**

At extraction date, 613 HRF patients were included in the JIRcohort: 524 FMF patients, 45 MKD patients, and 44 TRAPS patients. Ninety-three patients, male-to-female ratio 40/53, were treated with IL-1 inhibitors and had a follow-up in French (N = 71, 76.3%) and Swiss (N = 22, 30.1%) centers. Fifty (53.8%) had a diagnosis of FMF, 29 (30.9%) of MKD, and 14 (14.9%) of TRAPS. First symptoms appeared at a median age of 3.5 (2–35) years for FMF, 0.4 (5–40) years for MKD, and 2 (1–17) years for TRAPS. The median delay to diagnosis was the longest for patients with TRAPS [14.5 (0.2–47) years]. The median time of follow-up was 9 (1–60) years for all patients. Sixteen (17.2%) patients had associated secondary amyloidosis, mainly adults with FMF.

For FMF, 31 patients (62%) had a confirmatory genotype, five patients (10%) had a non-confirmatory genotype, 10 patients (20%) were not tested, and the genotype was not specified in four patients (8%). For MKD, 18 patients (62.1%) had a confirmatory genotype, three patients (10.3%) had a non-confirmatory genotype, four patients (13.8%) were not tested, and the genotype was not specified in four patients (13.8%). For TRAPS, seven patients (50%) had a confirmatory genotype, four patients (28.6%) had a non-confirmatory genotype, two patients (14.3%) were not tested, and the genotype was not specified in one patient (7.1%). The main clinical characteristics are detailed in Table 1.

**Literature Review**

One thousand two hundred eighty-one patients were identified in 112 articles, including 75 case reports and case series (11, 11, 17–88), 31 cohort studies (10, 89–119), four phase II trials (99, 120–122), and two randomized placebo-controlled trials (9, 12). Seven hundred ninety patients (61.7%) were diagnosed with FMF, 265 (20.7%) with MKD, and 226 (17.6%) with TRAPS. Five hundred sixty-nine came from central Europe (44.4%), 520 from the Eastern Mediterranean area (Israel, Turkey, 40.6%), six from Asia (China, Japan, 0.5%), three from the United States and Australia (0.2%), and 185 from an international registry (Eurofever, 14.4%). Three hundred fifty-eight patients (27.9%) had secondary amyloidosis, mostly FMF (n = 320/790).

---

**Table 1**

Main characteristics: JIRcohort and literature review. IL, interleukin; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; TRAPS, tumor necrosis factor receptor-associated periodic syndrome.

| Characteristics       | FMF (N = 50) | MKD (N = 265) | TRAPS (N = 226) |
|-----------------------|-------------|---------------|-----------------|
| **AID, median (interval, year)** |
| Age at diagnosis      | 6.5 (3.3–60) | 11.5 (1–74)   | 21.5 (2–47)     |
| Diagnostic time       | 5 (0–54)    | 14.5 (0.2–45) |                 |
| Follow-up time        | 7 (0.5–18)  | 9 (0.5–43)    | 6 (1–13)        |
| N attack/year         | 15 (3–24)   | 15 (3–24)     | 10 (1–57)       |
| **Genetic status**    |
| Confirmatory          | 18 (62.1)   | 250 (94.3)    | 7 (50)          |
| Non-confirmatory      | 3 (10.3)    | 1 (0.4)       | 4 (28.6)        |
| Not specified         | 4 (13.8)    | 14 (5.3)      | 1 (7.1)         |
| Not tested            | 0           | 0             | 2 (14.3)        |
| **Amyloidosis**       |
| Anakinra              | 6 (20.7)    | 144 (64.3)    | 7 (50)          |
| On demand             | 20          |               | 114 (50.4)      |
| Canakinumab           | 24 (7.8)    | 0             | 3               |
| Both                  | 12 (41.4)   | 28 (10.8)     | 4 (28.6)        |
| Ana > Can             | 12          | 28            | 2               |
| Can > Ana             | 0           | 0             | 2               |

---

*Vinit et al. Intereukin-1 Blockers in Hereditary Recurrent Fevers*
For FMF, 593 patients (75.1%) had a confirmatory genotype, 45 patients (5.7%) had a non-confirmatory genotype, and the genotype was not specified in 152 patients (19.2%). For MKD, 250 patients (94.3%) had a confirmatory genotype, one patient (0.4%) had a non-confirmatory genotype, and the genotype was not specified in 14 patients (5.3%). For TRAPS, 146 patients (64.6%) had a confirmatory genotype, 21 patients (9.3%) had a non-confirmatory genotype, and the genotype was not specified in 59 patients (26.1%). All patients were tested in the literature review for FMF, MKD, and TRAPS. The main characteristics are reported in Table 1.

### Interleukin-1-Blocking Agents

Anakinra was the principal IL-1-blocking agent reported in the literature (n = 754, 58.9%), sometimes used as on-demand therapy (n = 39/754 patients in the literature and 39/93 in the JIRcohort). Patients who received both IL-1 inhibitors were almost exclusively treated with anakinra before canakinumab (n = 109/112 patients in the literature and 24/26 in the JIRcohort). In the JIRcohort, IL-1 inhibitors were mainly used off-label for 87.1% of patients (n = 81/93), including 95.8% in France (n = 68/71) and 59.1% in Switzerland (n = 13/22). Median age at the first use of an IL-1 inhibitor occurred later for FMF patients [30 (4–82) years] than for MKD [11.5 (0.7–57) years] or TRAPS [13 (3–51) years] patients. Reasons for use of IL-1 inhibitors could be classified into four main categories and were similar in both JIRcohort and literature, i.e., failure of previous treatment, serious complications or comorbidities, the persistence of clinical and/or biological activity, and decreased quality of life (Tables 2, 3).

### Previous Treatments

#### Colchicine and Familial Mediterranean Fever JIRcohort

Forty-one FMF patients (82%) were identified as colchicine-resistant, even if this characteristic was not explained in detail in the JIRcohort. Twenty-seven patients (54%) had frequent attacks according to their treating physician, of whom eight had 0.25–1 attack/month, eight patients had 1–3 attacks/month, and three had ≥4 attacks/month. Colchicine was continued in combination with the IL-1 inhibitors in almost all patients (n = 46, 92%). Colchicine toxicity was reported in five (10%) patients (diarrhea, n = 2; polyneuropathy, n = 2; and rhabdomyolysis, n = 1).

#### Literature Review

Seven hundred thirty-one FMF patients (93.5%) were identified as colchicine-resistant. The frequency of febrile attacks, the maximum tolerated dose (1–3 mg/day), and patient adherence to treatment (Figure 1A) characterized colchicine resistance. The frequency of attacks was defined in n = 399 (54.6%) patients: ≥1/month (n = 67), ≥2/month (n = 24), ≥3/month (n = 228), ≥4/month (n = 19), ≥6/month (n = 7), and ≥12/month (n = 1). Colchicine toxicity was reported in 172 patients (21.8%), mainly diarrhea, neuromyositis, neutropenia, cardiomyopathy, myopathy, hepatic cytolysis, and asthenozoospermia.

### Other Previous Treatments

#### JIRcohort

Seven FMF patients (14%), 12 MKD patients (41.4%), and eight TRAPS patients (57.1%) were treated with immunosuppressive drugs and/or biological disease-modifying antirheumatic drugs...
(DMARDs) before IL-1 inhibitors, as detailed in Figure 1B. Reasons for discontinuation of previous treatments were ineffectiveness according to the treating physician (n = 16, 17.2%), a severe side effect (n = 2 for corticosteroids in an MKD patient and a TRAPS patient), or patient’s refusal (n = 1 MKD patient for corticosteroids). Reasons for discontinuation were not specified for nine patients (12.3%).

**Literature Review**

One hundred four FMF patients (13.2%), 117 MKD patients (44.2%), and 81 TRAPS patients (35.8%) were treated with immunosuppressive drugs and/or biotherapy before IL-1 inhibitors, as detailed in Figure 1B. Previous treatment was mainly stopped for therapeutic failure (n = 104 for FMF, n = 117 for MKD, and n = 81 for TRAPS). Nine patients (TRAPS, n = 8; MKD, n = 1) experienced a severe generalized urticarial rash, believed to be related to etanercept. Reasons for discontinuing steroid therapy are detailed in Figure 1C.

**Reasons for Discontinuing Anakinra**

Reasons for discontinuing anakinra are detailed in Figure 1D and were not specified for 7/24 patients (29.2%) in the JIRcohort. In the literature, the most common side effect was painful reactions at the injection site.

**Severe Clinical Complications**

**JIRcohort**

Severe clinical complications or comorbidities prompted the introduction of IL-1 inhibitors in 29 FMF patients (58%), six MKD patients (20.7%), and three TRAPS patients (21.4%) in the JIRcohort (Figure 2A). Gastroenterological complications found in FMF were peritonitis (n = 7), severe chronic diarrhea (n = 2), ulcerative colitis (n = 1), and cirrhosis (n = 2). Cerebellar ataxia has been found in one MKD patient. Three FMF patients had active spondylitis, three had severe vasculitis (Henoch–Schönlein purpura or polyarteritis nodosa), one had Still’s disease, and two others had active inflammatory bowel disease.

**Literature Review**

Severe clinical complications or comorbidities prompted the introduction of IL-1 inhibitors in 305 FMF patients (38.6%), 62 MKD patients (23.4%), and 23 TRAPS patients (10.2%) (Figure 2A). Gastroenterological complications found in MKD were recurrent anal abscesses (n = 1), intestinal fistula and/or necrosis (n = 33), severe colitis (n = 4), and refractory ascites (n = 1). In FMF, severe colitis was found in 16 patients. Musculoskeletal symptoms were mainly reported in FMF patients, arthritis (n = 55) or protracted febrile myalgia (n = 22). Eighteen patients (1.5%) had an associated active inflammatory disease, leading to the introduction of IL-1 inhibitors: spondylitis (n = 6), Behçet syndrome (n = 6), and Henoch–Schönlein purpura (n = 1) for FMF patients and destructive polyarthritis (n = 10) for MKD patients. On-demand anakinra was used in one MKD patient to prevent a severe attack triggered by immunization.

**Biological Characteristics**

**JIRcohort**

Persistent biological inflammation in-between attacks was reported in 46 patients (49.5%) including 27 FMF patients, 12 MKD patients, and seven TRAPS patients, mainly assessed by CRP levels >10 mg/L (Figure 3A).
FIGURE 1 | (A) FMF—Definition of colchicine resistance and literature review. (B) Previous treatments to IL-1 inhibitors. (C) Reasons for discontinuing steroids—Literature review. (D) Reasons for discontinuing anakinra. IL, interleukin; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; TRAPS, tumor necrosis factor receptor-associated periodic syndrome; LR, literature review.

FIGURE 2 | (A) Severe clinical complications. (B) Attacks’ characteristics—literature review. (C) Decreased quality of life. FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; TRAPS, tumor necrosis factor receptor-associated periodic syndrome; LR, literature review; GNMF, membrano-proliferative glomerulonephritis; MAS, macrophage activation syndrome; AMD, auto-immune disease.
Literature Review

The persistence of biological inflammation in-between attacks (n = 396, 30.9%) or its significant elevation during attacks (n = 363, 28.3%) led to the introduction of IL-1 inhibitors. Inflammation levels could be specific according to papers (CRP or SAA >10, 20, 25, or 30 mg/L) or any increased CRP/SAA level was sufficient (Figure 3A).

Disease Activity

JIRcohort

Reported for only 19 patients (20.3% of the cohort), the VAS was >3/10 in seven FMF patients (14%), five MKD patients (17.2%), and one TRAPS patient (7.1%). Disease status, intensity, and time course were also assessed by the physician as described in Figure 3B.

Literature Review

The Physician Global Assessment (PGA) scale—used in most studies—was ≥2 for n = 190 patients (14.8%), and the VAS was reported for n = 118 patients (9.2%). The AIDAI score was exploited in 29 FMF and two TRAPS, and HRF activity was evaluated for 86 patients with a non-standardized score, which was different from one paper to another. These scores were consistently high but could not be compared with one another, as they were not standardized.

Inflammatory Flares’ Characteristics

In the literature, a documented trigger (n = 15, FMF), continuous attacks (n = 32, MKD and n = 27, TRAPS), prolonged (n = 1, MKD and n = 2, TRAPS) or frequent (n = 203, MKD and n = 121, TRAPS) attacks could justify the introduction of anakinra or canakinumab (Figure 2B).

Quality of Life Assessment

JIRcohort

In 36 patients (38.7%; 19 FMF, 13 MKD, and four TRAPS), decreased quality of life contributed to the use of IL-1 inhibitors (Figure 2C). Two patients received on-demand anakinra to support school exams.

Literature Review

Decreased quality of life led to the start of IL-1 inhibitors in 100 patients (7.8%; 46 FMF, 46 MKD, and eight TRAPS) (Figure 2C). Different scores were used to evaluate the improvement of quality of life with IL-1 inhibitors: Short-Form 36 (SF36; n = 104 patients), Child Health Questionnaire-Parent Form 50 (CHQ-PF50; n = 32 patients), Health Assessment Questionnaire (HAQ; n = 13 patients), VAS (n = 30 patients), and social development (n = 71 patients).

DISCUSSION

To the best of our knowledge, this is the first paper describing extensively the criteria that lead in daily clinical practice to an indication of IL-1 blockers for adult and pediatric patients with FMF, MKD, and TRAPS. This work confirms that the reasons leading to the choice of treatment are considerably heterogeneous. However, four main categories seem to be consensual in both the JIRcohort and the literature: failure of previous treatment, a severe complication of the disease or associated comorbidity, persistent clinical and/or biological inflammation, and decrease in patients’ quality of life.

Persistent elevation of inflammatory markers and frequent attacks were the most common arguments for introducing IL-1
Inhibitors. Inflammation was mainly judged on CRP levels, whose duration and severity depended on each prescriber or study. A clear definition of “frequent attacks” was rarely available, and when it did exist, the number of flares, duration, intensity, and time of onset were very heterogeneous. Recommendations for the management of MKD and TRAPS are also imprecise, as IL-1 inhibitors are required for “frequent attacks and/or subclinical inflammation between attacks” (123–125).

For FMF, IL-1 blockers are indicated only for colchicine resistance or intolerance; however, there is currently no consensus in the literature for a clear definition of crFMF. According to the Franco-Israeli consortium, crFMF is defined as the occurrence of six or more typical attacks in 1 year or three in 4–6 months associated with an increase in inflammatory markers between attacks (126); according to European Alliance of Associations for Rheumatology (EULAR) definition, as at least one flare per month in the last 6 months with full compliance to treatment (127) and as more than six attacks per year or more than four attacks in the last 6 months with persistent biological inflammation (128). Recently, Ozen et al. (129) agreed that crFMF included recurrent attacks (one or more attacks per month over 3 months) or persistent laboratory inflammation in-between attacks. Eighty-two percent of patients receiving IL1 inhibitors were considered crFMF in our study, similar to results (89%) of Kacar et al. (130). However, many factors could contribute to insufficient response to colchicine: lack of compliance, the occurrence of side effects, drug interactions, genetic factors, and environmental factors (infections, stress, and diet) (131). All studies and definitions agree that a maximum tolerated dosing of colchicine (132) and the assessment of compliance are the prerequisites before discussing crFMF (133), but finding a standardized way is challenging (134). Missing tablet count, Morisky score (135), and colchicine dosage in the hair were rarely reported in our study. Hair colchicine testing was recently proposed (136) to assess objectively and non-invasively adherence from 2 to 6 months before the sampling. Toxicity of colchicine is rare in our study, as approved by experts in the literature (129).

Our study showed that only a proportion of patients appear to require IL-1 inhibition. Unfortunately, it was not feasible to estimate the exact ratio of patients requiring these treatments because we did not have the opportunity to verify that all patients from participating centers were included in the cohort. However, IL-1 inhibitors do not appear to be offered as first-line therapy to all patients in daily practice. One reason could be that at the time of the persistent HRF activity, IL-1 inhibitors were not always available in all centers. Steroids and TNF-α blockers were mainly used before IL-1 inhibitors in our study. Steroids can be used shortly for flares’ treatment but may only have partial efficacy in MKD (10, 100) and a declining efficacy in TRAPS, requiring a higher dose for an equivalent response with many side effects (125). Efficacy of etanercept in TRAPS patients appears transient and decreases over time (137, 138), confirmed in our study with the reappearance of inflammatory flares. A better clinical and biological response also has been described by Ozen et al. (96) with an IL-1 rather than a TNFα inhibitor in TRAPS patients on first-line therapy, which also represent by far the most frequently employed biologics in the Auto-Inflammatory Diseases Alliance (AIDA) network (139). IL-1 inhibitors could be recommended as first-line therapy and for cortisone sparing in severe phenotypes (96).

A severe phenotype of HRF justified IL-1 inhibitors in about 30% of patients in the JIRcohort and the literature. Active inflammatory comorbidities found in our study have been known to be associated with FMF, vasculitis [Behçet’s disease (140), Henoch–Schönlein purpura, periarteritis nodosa (141)], spondylitis (142), and suppurative hidradenitis (143), whereas inflammatory bowel diseases (144) and multiple sclerosis (145) are still controversial. As recommended (127), intensified treatment with biological DMARDs was given in 26% of FMF patients with secondary amyloidosis in the JIRcohort. Similar results (20%) were found in the study by Corsia et al. (128). Such a therapeutic strategy has proven its effectiveness, as shown by a recent study, in which treatment with canakinumab was significantly associated with decreased proteinuria in secondary amyloidosis patients (111). In TRAPS patients complicated with amyloidosis, especially in the case of structural mutation involving cysteine (124), IL-1 inhibitors also appeared to be the most effective treatment (41, 146–148). The majority of patients in our cohort as well as those in the literature requiring IL-1 inhibition had a confirmatory genotype according to the International Study Group for Systemic Autoinflammatory Diseases (INSAID) rules. The need for this type of treatment in patients with a non-confirmatory genotype [heterozygous FMF or MKD without mevalonic aciduria, presence of a variant of uncertain significance (VOUS) in TRAPS] seems much more uncommon. The few patients classified in our cohort as having “no mutation” concern patients (i) for whom the diagnosis was made before the generalization of genetic testing and who were never tested afterward or (ii) for whom genetics was missing data.

Several (sometimes non-standardized) scores were recorded to measure disease activity and lead to IL-1 inhibitor treatment. VAS, the most frequently used score in the JIRcohort, has the disadvantage of trying to assign a single value to a complex and subjective perception of the disease, causing disparate therapeutic decisions depending on the prescriber. The FMF50, which defines non-responders to colchicine (149), and adult (150, 151) or pediatric (152) severity scores such as the International Severity Score for FMF (ISSF) are not very sensitive (153). With a sensitivity and specificity of more than 80%, the AIDAI score differentiates patients with active disease (score >9) from those with inactive disease (score <9) (154). Despite its validation and possible use in daily practice, it seems difficult to have it completed daily by patients. Furthermore, the AIDAI score has not yet been validated in a treat-to-target approach: the maximal cutoff value and the specificity of the score for the inflammatory manifestations are still unknown.

There is currently no score evaluating disease activity from both physician’s and patient’s perspective, taking into account the quality of life, which was a strong argument in our study for...
introducing IL-1 inhibitors. Several authors confirmed a poorer quality of life in children and adults with FMF (155–158) and a higher incidence of anxiety and depression (159–161) that may lead to more frequent attacks with higher rates of CRP and SAA (159, 161, 162). Van der Hilst et al. (10) also described lower autonomy and social development in MKD patients. Estimating quality of life in HRF is complex, involved disease activity and severity, and would require a standardized assessment to justify therapeutic escalation and improve management.

Even if canakinumab is today the only IL-1 inhibitor to have MA in Europe for treatment of MKD and TRAPS, nearly two-thirds of patients in our cohort were treated with anakinra as a first-line. There is so far no data comparing the two drugs that both seem to be effective in these HRFs (9–12, 32, 46, 54, 55, 60, 100, 104, 105, 133, 163, 164), but their costs differ. Anakinra has a shorter half-life, limiting drug overdosing in patients with renal impairment (94, 113, 165), and the French–Israeli expert committee recommends its use for crFMF patients before considering a long-half-life IL-1 inhibitor (126). Canakinumab is an alternative in case of poor tolerance of daily anakinra injections. The efficacy of anakinra prescribed on demand has been described in cases of known triggers [stress of an examination or vaccinations (56)] or rare inflammatory flares (78, 84, 103). On-demand prescribing may limit local reactions to injections, decrease the use of steroids and the risk of infection, but there are currently no studies comparing anakinra on-demand vs. continuous use. However, experts recommend continuous treatment for persistent inflammatory syndrome between attacks or the use of anakinra on demand more than once a month (123, 124). Considering its benefits and efficacy, anakinra may also soon be granted MA for MKD and TRAPS.

The major flaw of our study is its retrospective design. Since the collection of data in the JIRcohort began in April 2016, the clinical, biological, and quality of life characteristics of patients treated with IL-1 inhibitors before this date were not captured. The heterogeneity of experience in managing HRF patients among different centers and the lack of follow-up tools in the JIRcohort are also part of the limitations of our study. The strengths of our study are the large sample of both children and adults and its multicentric dimension, including countries with different market authorizations.

**CONCLUSION**

Our study has shown that the indications in real life for the use of IL-1 inhibitors in crFMF, MKD, and TRAPS are still not standardized and poorly defined. The choice for treatment with IL-1 inhibitors is based on the habits of expert clinicians that may vary from one center to another. Furthermore, the availability of the drugs may vary from country to country. Several prerequisites will be necessary to harmonize clinical care: (i) a formalization of the different criteria that clinicians use to set the indication for IL-1 inhibition in HRFs, (ii) validated composite activity scores that will eventually help to define treat-to-target treatment plans, (iii) a comparison of the different treat-to-target strategies on the actual long-term outcome of the patients, and (iv) a medico-economic analysis of the different possible treatment plans. We recently launched a European-wide survey to collect treatment plans and outcome measures applied to patients with HRF. We will hence provide a snapshot of current care and clinical practice strategies in Europe. In the long term, comparing the different strategies used will guarantee the patients with autoinflammatory diseases to be offered the optimal treatment available in their country.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

All authors participated in the preparation of the manuscript. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

Michael Hofer, Pierre Quartier, Isabelle Melki, Dalbal Benazzouz, François Hofer, Sabrina Atmame, Rim Bourguiba, RES Foundation.

**REFERENCES**

1. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. *Cell* (1999) 97(1):133–44. doi: 10.1016/S0092-8674(00)80721-7.
2. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-Receptor Antagonist in the Muckle-Wells Syndrome. *N Engl J Med* (2003) 348(25):2583–4. doi: 10.1056/NEJM20030619348252532.
3. Jesus AA, Goldbach-Mansky R. IL-1 Blockade in Autoinflammatory Syndromes. *Arthritis Rheumatol* (2014) 65:223–4. doi: 10.1002/art.38993.
4. Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety Profile of the Interleukin-1 Inhibitors Anakinra and Canakinumab in Real-Life Clinical Practice: A Nationwide Multicenter Retrospective Observational Study. *Clin Rheumatol* (2018) 37(8):2233–40. doi: 10.1007/s10067-018-4119-x.
5. Malcova H, Strizova Z, Milota T, Striz I, Sediva A, Cebecauerova D, et al. IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives. *Front Immunol* (2020) 11:619257. doi: 10.3389/fimmu.2020.619257.
6. Marko L, Shemer A, Lidar M, Grossman C, Druyan A, Livneh A, et al. Anakinra for Colchicine Refractory Familial Mediterranean Fever: A Single-Centre Real-Life Study With 44 Patients. *Rheumatol Oxf Engl* (2021) 60(6):2878–83. doi: 10.1093/rheumatology/keaa728.
7. Atas N, Erogul GA, Sodaq HN, Ozurtok BO, Babaoğlu H, Satis H, et al. Long-Term Safety and Efficacy of Anakinra and Canakinumab in Patients With Familial Mediterranean Fever: A Single-Centre Real-Life Study With 101 Patients. *Clin Exp Rheumatol* (2021) 39 Suppl 132(5):30–6.
8. PNDS - Syndromes Periodiques Associes a La Cryopyrinne (CAPS), Vol. 73 (2013). Available at: https://www.has-sante.fr/upload/docs/application/pdf/
Vinit et al. Intereukin-1 Blockers in Hereditary Recurrent Fevers

10. van der Hasselt JCH, Boron DS, Krenkel J, Drenth JPH, van der Meer JWM, et al. Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome. Med (Baltimore) (2008) 87(6):301–10. doi: 10.1097/MD.0b013e318190cfd7

11. Gattorno M, Petraglia MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent Efficacy of Anakinra in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome. Arthritis Rheumatol (2008) 58(5):1516–20. doi: 10.1002/art.23475

12. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med (2018) 378(20):1908–19. doi: 10.1056/NEJMoai1706314

13. Ozcan S, Demir S. Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient. Paediatr Drugs (2017) 19(4):303–11. doi: 10.1007/s40272-017-0232-6

14. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification Criteria for Autoinflammatory Recurrent Fevers. Ann Rheum Dis (2019) 78(8):1025–32. doi: 10.1136/annrheumdis-2019-215048

15. Van Gijn ME, Ceccherini I, Shinar Y, Carbo EC, Slofstra M, Arostegui JI, et al. The Efficacy of Canakinumab in an Adolescent With Colchicine-Resistant Familial Mediterranean Fever: Effective But Risky. Eur J Clin Invest (2007) 37(11):912–4. doi: 10.1111/j.1365-2362.2007.01868.x

16. Czege JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 Domain of Pyrin, the Familial Mediterranean Fever Protein, Interacts Directly With Caspase-1 to Modulate IL-1beta Production. Proc Natl Acad Sci USA (2006) 103(26):9982–7. doi: 10.1073/pnas.0602081103

17. Dorairaj V, Botto MB, Cournil A, Veres R. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. Biological. Eur J Rheumatol (2013) 45(1):117–30. doi: 10.1016/s1216-0385-y

18. Celebi ZK, Kucukahsin O, Sengul S, Tuzuner A, Keven K. Colchicine-Resistant Familial Mediterranean Fever in a Renal Transplantation Patient: Successful Treatment With Anakinra. Clin Kidney J (2014) 7(2):219–20. doi: 10.1093/ckj/sft164

19. Mercan R, Turan A, Bitik B, Tufan A, Haznedaroğlu S, Goker B. Rapid Resolution of Protracted Febrile Myalgia Syndrome With Anakinra: Report of Two Cases. Mod Rheumatol (2016) 26(3):458–9. doi: 10.3109/14397959.2014.882221

20. Sevillano AM, Hernandez E, Gonzalez E, Mateo I, Gutierrez E, Morales E, et al. Anakinra Induces Complete Remission of Nephrotic Syndrome in a Patient With Familial Mediterranean Fever and Amyloidosis. Nefrol Publicacion De Soc Espanola Nefrol (2016) 36(1):63–6. doi: 10.1016/j.j nefro.2015.10.005

21. Alpa M, Roccatello D. Canakinumab as Rescue Therapy in Familial Mediterranean Fever Refractory to Conventional Treatment. Drug Des Devel Ther (2015) 9:1983–7. doi: 10.2147/DDDT.S96117

22. Jeunenak M, Hrubiskova K, Kapustova L, Kostkova M, Banovcin P, Kanavcic M. Anakinra as Monotherapy for Treatment of Familial Mediterranean Fever - First Report in Central and Eastern Europe Region. Bratisl Lek Listy (2018) 119(4):198–200. doi: 10.4149/BLL_2018_036

23. Sozleri B, Gulez N, Ergin M, Serdaroglu E. The Experience of Canakinumab in Renal Amyloidosis Secondary to Familial Mediterranean Fever. Mol Cell Pediatr (2016) 3(1):33. doi: 10.1186/s40348-016-0058-2

24. Heuchamdioglu DO, Ozcan S. Canakinumab Induces Remission in a Patient With Resistant Familial Mediterranean Fever. Rheumatol Oxf Engl (2012) 51(6):1041. doi: 10.1093/rheumatology/ker621

25. Georgin-Lavialle S, Stankovic Stojanovic K, Bachmeyer C, Sellam J, Abbara M, Banovcin P. Anakinra As Monotherapy For Treatment Of Familial Mediterranean Fever: Successful Treatment With Anakinra. Rheumatol Oxf Engl (2017) 56(1):167–9. doi: 10.1093/rheumatology/kew290

26. Abbara S, Georgin-Lavialle S, Stankovic Stojanovic K, Bachmeyer C, Senet P, Buob D, et al. Association of Hidradenitis Suppurativa and Familial Mediterranean Fever: A Case Series of 6 Patients. J Bone Spine Rev Bum (2017) 84(2):159–62. doi: 10.1016/j.jsbpm.2016.02.021

27. Espildora-Hernández J, Abarca-Costalago M. Familial Mediterranean Fever Treated With Anakinra: A Case Report. Reumatol Clin (2017) 13(2):120–1. doi: 10.1016/j.reuma.2016.06.061

28. Gentileschi S, Rigante D, Vitale A, Sota J, Frediani B, Galeazzi M, et al. Efficacy and Safety of Anakinra in Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) Complicated by Severe Renal Failure: A Report After Long-Term Follow-Up and Review of the Literature. Clin Rheumatol (2017) 36(7):1687–90. doi: 10.1007/s10067-017-3688-4

29. Campurbi D, Mitjavila F, Arostegui JL, Corbella X. Efficacy of Anakinra in an Adult Patient With Recurrent Pericarditis and Cardiac Tamponade as Initial Manifestations of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome Due to the R92Q TNFRSF1A Variant. Int J Rheum Dis (2017) 20(5):404–4. doi: 10.1111/1756-187X.13029

30. Cataldi M, Meini A, Monari P, Guidali G, Arisi M, Pelucchi F, et al. Recurrent Migratory Angioedema as Cutaneous Manifestation in a Familial Case of TRAPS: Dramatic Response to Anakinra. Dermatol Online J (2013) 19(11):20405.
80. Cakan M, Karadag SG, Ayaz NA. Corticosteroid-Resistant Anakinra-Responsive Protracted Febrile Myalgia Syndrome as the First Manifestation of Familial Mediterranean Fever. North Clin Istanbul (2019) 7 (1):174-179. doi: 10.41744/nci.2019.38243
81. Kaly L, Rozenbaum M, Kumar D, Slobodin G, Boulman N, Awiast A, et al. Ulcerative Colitis and Familial Mediterranean Fever: Can Anakinra Treat Both? ACG Case Rep J (2019) 6(7):e00143. doi: 10.14398/acgcaseprep2019.00143
82. Coppola T, Becken B, Van Mater H, McDonald MT, Panayoti GM. A Case Report of Mevalonate Kinase Deficiency in a 14-Month-Old Female With Fever and Lower Extremity Weakness. BMC Pediatr (2019) 19(1):245. doi: 10.1186/s12887-019-1617-1
83. Maggio MC, Ceccherini I, Grossi A, Gattorno M, Corsello G. PAPA and Mediterranean Fever-Related Amyloidosis. Clin Rheumatol (2010) 29(10):1181–1185. doi: 10.1007/s10067-010-1858-z
84. Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jean-François Poignard P. Targeting Interleukin-1 Inhibitors in Familial Mediterranean Fever: A Case Series and a Review of the Literature. Semin Arthritis Rheumat (2011) 41 (2):265–71. doi: 10.1016/j.semarthrit.2010.11.003
85. Özcan, S. Güngör, N., and Sari, İ. et al. Efﬁcacy and Safety of Canakinumab in Patients With TNF Receptor-Associated Periodic Syndrome (TRAPS): An Open-Label, Phase II Study. Ann Rheum Dis (2017) 76(1):173–8. doi: 10.1136/annrheumdis-2015-209031
86. Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, et al. Treatment of Autoinﬂammatory Diseases: Results From the Eurofever Registry and a Literature Review. Ann Rheum Dis (2013) 72(5):678–85. doi: 10.1136/annrheumdis-2011-201268
87. Gattorno M, Obici L, Meini A, Tormey V, Abrams K, Davis N, et al. THU0396 Efficacy and Safety of Canakinumab in Patients With TNF Receptor Associated Periodic Syndrome (TRAPS). Ann Rheum Dis (2013) 72(Suppl 3):289–9. doi: 10.1136/annrheumdis-2012-eular.2361
88. Ugurlu S, Seyahi E, Hatemi G, Haciloglu A, Akcok NF, Ozdogan H. THU0402 Canakinumab Therapy in Patients With Familial Mediterranean Fever. Ann Rheum Dis (2014) 73(Suppl 2):S30–1. doi: 10.1136/annrheumdis-2014-eular.5654
89. Bozarsan E, Aksoy E, Aksoy A, et al. Efﬁcacy of Continuous Interleukin-1 Blockade in Mevalonate Kinase Deﬁciency. Rheumatol (2015) 128(1):e152–6. doi: 10.1093/rheumatology/ket097
90. Bader-Meunier B, Florkin B, Sibilia J, Acquaviva C, Hachulla E, Grateau G, et al. Mevalonate Kinase Deﬁciency: A Survey of 50 Patients. Pediatrics (2011) 128(1):e152–159. doi: 10.1542/peds.2010-3639
91. Deshayes S, Georgin-Lavaillé S, Hot A, Durel C-A, Hachulla E, Rouanes N, et al. Efﬁcacy of Continuous Interleukin-1 Blockade in Mevalonate Kinase Deﬁciency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. J Rheumatol (2018) 45(3):425–9. doi: 10.3899/jrheum.170684
92. Ter Haar NM, Jeyaratnam J, Lachmann HJ, Simon A, Brogan PA, Doglio M, et al. The Phenotype and Genotype of Mevalonate Kinase Deﬁciency: A Series of 114 Cases From the Eurofever Registry. Arthritis Rheumatol (2016) 68(11):2795–805. doi: 10.1002/art.39763
93. Ergezen B, Ugurlu S, Ozdogan H. FRI0596 Anakinra Treatment in Patients With Familial Mediterranean Fever: A Single-Center Experience (Case Report). Ann Rheum Dis (2017) 76(Suppl 2):714–5. doi: 10.1136/annrheumdis-2017-eular.5436
94. Köhler BM, Lorenz H-M, Blank N. IL1-Blocking Therapy in Colchicine-Resistant Familial Mediterranean Fever. Eur J Rheumatol (2018) 5(4):230–4. doi: 10.5152/ejrheum.2018.18036
95. Babaoglu H, Varan O, Kucuk H, Atas N, Satis H, Salman R, et al. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study. J Clin Rheumatol (2018) 24(1):7–13. doi: 10.1097/RHU.0000000000000873
96. Varan Ö, Kucuk H, Babaoglu H, Gwen SC, Oztukut MA, Haznedaroglu S, et al. Efﬁcacy and Safety of Interleukin-1 Inhibitors in Familial Mediterranean Fever Patients Complicated With Amyloidosis. Mod Rheumatol (2019) 29(2):363–6. doi: 10.1007/s10029-018-2075-x
97. Günez N, Makay B, Sözeri B. Long-Term Effectiveness and Safety of Canakinumab in Pediatric Familial Mediterranean Fever Patients. Mod Rheumatol (2020) 30(1):166–71. doi: 10.1007/s10029-018-1559-488
98. Akar S, Cetin P, Kalyoncu U, Karadag O, Sari I, Cinar M, et al. Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care Res (2018) 70(7):1900–6. doi: 10.1002/art.33466
99. Berdeli A, Şenol O, Talay G. Treatment of Familial Mediterranean Fever With Canakinumab in Patients Who Are Unresponsive to Colchicine. Eur J Rheumatol (2019) 6(2):85–8. doi: 10.5152/ejrheum.2019.18190
149. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: A Score for Assessing Outcome in Familial Mediterranean Fever. *Ann Rheum Dis* (2014) 73(5):897–901. doi: 10.1136/annrheumdis-2013-204719

150. Pras E, Livneh A, Balow JE, Pras E, Kastner DL, Pras M, et al. Clinical Differences Between North African and Iraqi Jews With Familial Mediterranean Fever. *Ann J Med Genet* (1998) 75(2):216–9. doi: 10.1002/SIC11096-8628(19980113)75:2<216:Ahajmg20;3.0.CO;2-R

151. Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, et al. Evaluation of Disease Severity in Familial Mediterranean Fever. *Semin Arthritis Rheumatol* (2005) 35(1):57–64. doi: 10.1016/j.semarthrit.2005.02.002

152. Ozen S, Aktay N, Lainka E, Duzova A, Bakkaloglu A, Kallinich T. Disease Severity in Children and Adolescents With Familial Mediterranean Fever: A Comparative Study to Explore Environmental Effects on a Monogenic Disease. *Ann Rheum Dis* (2009) 68(2):246–8. doi: 10.1136/ard.2008.092031

153. Demirkaya E, Acikel C, Hashkes P, Gattorno M, Pras E, Ozdogan H, et al. Development and Initial Validation of International Severity Scoring System for Familial Mediterranean Fever (ISSF). *Ann Rheum Dis* (2016) 75(6):1051–6. doi: 10.1136/annrheumdis-2015-208671

154. Piram M, Koné-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kummerle-Deschner J, et al. Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for Hereditary Recurrent Fever Syndromes. *Ann Rheum Dis* (2014) 73(12):2168–73. doi: 10.1136/annrheumdis-2013-203666

155. Buskila D, Zaks N, Neumann I, Livneh A, Greenberg S, Pras M, et al. Quality of Life of Patients With Familial Mediterranean Fever. *Clin Exp Rheumatol* (1997) 15(4):355–60.

156. Giese A, Kurucay M, Kilic L, Ornek A, Sendur SN, Lainka E, et al. Quality of Life in Adult Patients With Familial Mediterranean Fever Living in Germany or Turkey Compared to Healthy Subjects: A Study Evaluating the Effect of Disease Severity and Country of Residence. *Rheumatol Int* (2013) 33(7):1713–9. doi: 10.1007/s00296-012-2622-y

157. Sahin S, Yalcin I, Senel S, Ataseven H, Uslu A, Yildirim O, et al. Assessment Life Quality of Familial Mediterranean Fever Patients With Short Form-36 and its Relationship With Disease Parameters. *Eur Rev Med Pharmacol Sci* (2013) 17(7):958–63.

158. Yildirim DG, Bakkaloglu SA, Acar AS, Celik B, Buyan N. Evaluation of Quality of Life and Its Associations With Clinical Parameters in Pediatric Patients With Familial Mediterranean Fever. *North Clin Istab* (2021) 8(3):255–60. doi: 10.14744/nci.2020.90093

159. Makay B, Unsal E, Arslan N, Varni JW. Health-Related Quality of Life of School-Age Children With Familial Mediterranean Fever. *Clin Exp Rheumatol* (2009) 27(2 Suppl 33):S96–101.

160. Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B, Haznedaroğlu S, et al. Health-Related Quality of Life and Its Associations With Mood Condition in Familial Mediterranean Fever Patients. *Rheumatol Int* (2011) 31(3):623–8. doi: 10.1007/s00296-009-1334-4

161. Duruoz MT, Unal C, Bingül DK, Ulutatar F. Fatigue in Familial Mediterranean Fever and its Relations With Other Clinical Parameters. *Rheumatol Int* (2018) 38(1):75–81. doi: 10.1007/s00296-017-3882-3

162. Kucukaslan O, Omma A, Ozdemirel AE, Teker D, Ulutas S, Maras Y, et al. Incidence of Sleep Disturbances in Patients With Familial Mediterranean Fever and the Relation of Sleep Quality With Disease Activity. *Int J Rheum Dis* (2018) 21(10):1849–56. doi: 10.1111/1756-185X.13104

163. Koga T, Magita K, Kawakami A. Biologic Therapy in Familial Mediterranean Fever. *Mod Rheumatol* (2016) 26(5):637–41. doi: 10.3109/14397595.2016.1162261

164. Soriano A, Soriano M, Espinosa G, Manna R, Emmi G, Cantarini L, et al. Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. *Front Immunol* (2020) 11:865. doi: 10.3389/fimmu.2020.00865

165. Simsek C, Karatas M, Tatar E, Yildirim AM, Alkan FT, Uslu A. The Efficacy of Interleukin-1 Antagonist Drugs in Combination With Colchicine in Patients With FMF-AA With Colchicine Resistance After Kidney Transplantation: A Study With Histopathologic Evidence. *Clin Transplant* (2021) 35(6):e14309. doi: 10.1111/ctr.14309

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Vinit, Georgin-Lavialle, Theodoropoulou, Barbier, Belot, Mejiri, Pillet, Pachopnik, Poignant, Rebelle, Woerner, Koné-Paut and Hentgen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.